HOOK Stock Overview
A clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HOOKIPA Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.29 |
| 52 Week High | US$11.30 |
| 52 Week Low | US$2.08 |
| Beta | 0.83 |
| 11 Month Change | -39.55% |
| 3 Month Change | -59.56% |
| 1 Year Change | -55.51% |
| 33 Year Change | -92.90% |
| 5 Year Change | -97.65% |
| Change since IPO | -98.37% |
Recent News & Updates
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
Nov 19
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues
Sep 27Recent updates
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
Nov 19HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues
Sep 27The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%
Aug 13Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge
Jun 22HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth
Apr 28Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts
May 18Shareholder Returns
| HOOK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.4% | 4.0% | 2.2% |
| 1Y | -55.5% | 18.3% | 32.6% |
Return vs Industry: HOOK underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: HOOK underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| HOOK volatility | |
|---|---|
| HOOK Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HOOK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HOOK's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 165 | Malte Peters | www.hookipapharma.com |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.
HOOKIPA Pharma Inc. Fundamentals Summary
| HOOK fundamental statistics | |
|---|---|
| Market cap | US$25.92m |
| Earnings (TTM) | -US$43.37m |
| Revenue (TTM) | US$50.00m |
0.6x
P/S Ratio-0.6x
P/E RatioIs HOOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOOK income statement (TTM) | |
|---|---|
| Revenue | US$50.00m |
| Cost of Revenue | US$75.30m |
| Gross Profit | -US$25.30m |
| Other Expenses | US$18.07m |
| Earnings | -US$43.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.60 |
| Gross Margin | -50.60% |
| Net Profit Margin | -86.74% |
| Debt/Equity Ratio | 0% |
How did HOOK perform over the long term?
See historical performance and comparison